Jun 03, 2019 / 11:00PM GMT
Karl Mahler - Roche Holding AG - Head of IR
Good evening. Ladies and gentlemen, warm welcome from my side. My name is Karl Mahler, I'm the Head of Investor Relations. Looking around, we have about 170, 180 people. So it's pretty good. Can you hear me? Or is it difficult? There is an echo, right? Maybe you can try to get rid of the echo. Okay. I'll just continue on.
So as every year, we have prepared some dinner for you outside, which gives you the opportunity to mix and mingle with the speakers. That gives you the opportunity to address basically any kind of question which you couldn't address here in the auditorium. And the plan for today is about 45 minutes presentation; 45 minutes Q&A; and then as I said, going out and getting something to eat and drink.
So this year -- hopefully I can manage. This year's ASCO, as for my impression, is a bit more light than that what we had in the past years for every company. But I have to say looking at what was, in the end, presented, it was also not so bad. We -- in hematology, we will present tomorrow the CLL14 data, VENCLEXTA plus GAZYVA.
Roche Holding AG Analyst Event at ASCO 2019 Transcript
Jun 04, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers